

Lifelong Learning in Endocrinology

Table of Contents

Riesgo cardiorrenal en diabetes

Full Text:

1 Ala M, SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD, *Endocrinology*, Volume 162, Issue 12, December 2021, bqab157, <https://doi.org/10.1210/endocr/bqab157>

2 Nayana Khurana, Steven James, Melinda T Coughlan, Richard J MacIsaac, Elif I Ekinci, Novel Therapies for Kidney Disease in People With Diabetes, *The Journal of Clinical Endocrinology & Metabolism*, Volume 107, Issue 1, January 2022, Pages e1–e24, <https://doi.org/10.1210/clinem/dgab639>.

Abstracts:

1. Cha AS, Chen Y, Fazioli K, Rivara MB, Devine EB. Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes. *J Clin Endocrinol Metab*. 2021 Mar 25;106(4):1225-1234. doi: 10.1210/clinem/dgaa894. PMID: 33248440.

2. Cintra RM, Nogueira AC, Bonilha I, Luchiari BM, Coelho-Filho OR, Coelho OR, Schwartzmann P, Muscellie E, Nadruz W, Carvalho LSF, Sposito AC. Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years. *J Clin Endocrinol Metab*. 2021 Sep 27;106(10):3060-3067. doi: 10.1210/clinem/dgab428. PMID: 34125217.

3. Konig, M., Riddle, M.C., Colhoun, H.M. et al. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. *Cardiovasc Diabetol* 20, 194 (2021). <https://doi.org/10.1186/s12933-021-01386-4>

4. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. *Circulation*. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. PMID: 33198491; PMCID: PMC7864612.

5. Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M,

Ferreira JP, Pocock SJ, Zannad F, Packer M. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. *Circulation*. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11. PMID: 33175585; PMCID: PMC7834911.

6. Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. *Diabetes Care*. 2021 May;44(5):1159-1167. doi: 10.2337/dc20-2492. Epub 2021 Mar 2. PMID: 33653824.

7. Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt B; SOLOIST-WHF committees and investigators. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. *Ann Intern Med*. 2021 Aug;174(8):1065-1072. doi: 10.7326/M21-0651. Epub 2021 Jun 22. PMID: 34152828.

8. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozd J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. *JAMA*. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906. Erratum in: *JAMA*. 2021 Apr 6;325(13):1335. PMID: 32219386; PMCID: PMC7157181.

9. . Hiddo J.L. Heerspink, Ph.D., Bergur V. Stefánsson, M.D., Ricardo Correa-Rotter, M.D., Glenn M. Chertow, M.D., Tom Greene, Ph.D., Fan-Fan Hou, M.D., Johannes F.E. Mann, M.D., John J.V. McMurray, M.D., Magnus Lindberg, M.Sc., Peter Rossing, M.D., C. David Sjöström, M.D., Roberto D. Toto, M.D., et al., for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2020; 383:1436-1446. DOI: 10.1056/NEJMoa2024816.

10. Birkeland, KI, Bodegard, J, Eriksson, JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. *Diabetes Obes Metab*. 2020; 22: 1607– 1618. <https://doi.org/10.1111/dom.14074>